Brokerages Set Moderna, Inc. (NASDAQ:MRNA) Target Price at $90.22

Shares of Moderna, Inc. (NASDAQ:MRNA) have been assigned an average rating of “Hold” from the twenty-two analysts that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $84.00.

Several equities research analysts have recently commented on the stock. Sanford C. Bernstein assumed coverage on shares of Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target for the company. Barclays lowered their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Leerink Partners reduced their price objective on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a research note on Monday, November 4th.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 2,930 shares of company stock worth $217,170 over the last ninety days. Insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Moderna

Institutional investors have recently modified their holdings of the business. Intrinsic Value Partners LLC lifted its position in Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after purchasing an additional 24,505 shares during the period. Banco Santander S.A. bought a new position in shares of Moderna in the third quarter worth about $3,550,000. John G Ullman & Associates Inc. lifted its holdings in shares of Moderna by 341.3% in the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after acquiring an additional 38,400 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after buying an additional 167,596 shares during the period. Finally, Vontobel Holding Ltd. increased its stake in shares of Moderna by 148.2% in the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after buying an additional 69,313 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

MRNA opened at $41.11 on Monday. Moderna has a 1-year low of $35.80 and a 1-year high of $170.47. The firm has a 50-day moving average price of $54.96 and a two-hundred day moving average price of $93.90. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the company earned ($1.39) EPS. Moderna’s revenue was up 3.8% on a year-over-year basis. As a group, analysts expect that Moderna will post -9.44 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.